FDA Clears New Plasma Protocol Software for Fenwal Alyx® System

  FDA Clears New Plasma Protocol Software for Fenwal Alyx® System

  Includes Expanded Two-Way Data Communication Supporting Electronic Records

Business Wire

LAKE ZURICH, Ill. -- November 19, 2013

Fenwal, Inc., a Fresenius Kabi company, announced today it has received FDA
510(k) clearance for the Alyx® system software version 3.1. The new software
gives the Alyx system a protocol for closed system plasma collection and
expanded data management capabilities. The Alyx system now includes three
procedures to help customers meet their collections needs: two units of red
blood cells, one unit of red blood cells with plasma, and plasma alone.

The Alyx system is used worldwide to collect life-saving blood components for
patient transfusion. Plasma collected on the Alyx system can be processed as
Fresh Frozen Plasma (FFP), Plasma Frozen within 24 hours of collection (PF24)
or Plasma Frozen within 24 hours of collection held at Room Temperature for 24
hours (PF24RT24).

“Alyx is a mobile, easy-to-use blood component collection system,” said Dean
Gregory, president, Medical Devices, for Fresenius Kabi North America. “With
this latest clearance, Alyx can now be used to collect up to 825mL of plasma
from a single donor, helping blood centers meet the growing hospital demand
for plasma. This is the latest of several regulatory clearances for Fenwal
products since becoming part of Fresenius Kabi and each is an example of our
commitment to advance transfusion medicine.”

The new Alyx system software supports remote procedure setup and paperless
documentation when used with the Fenwal DXT® Relay data exchange software and
a blood center’s blood establishment computer system (BECS). With remote
procedure setup, donor registration information may be entered remotely into
an Alyx instrument. This helps assure data accuracy, documentation compliance,
and streamlines processes.

The DXT® Relay software also provides blood center professionals with
easy-to-read, on-demand reports that consolidate procedure data from multiple
Alyx systems in different locations. The reports track performance indicators
and may be used to identify opportunities for operational improvement and
training. The DXT® Relay software was built with open architecture so it is
integrated seamlessly with existing blood center systems. Once integrated with
a center’s BECS, DXT Relay can provide data that will meet regulatory
requirements for paperless documentation.

Plasma is the liquid portion of blood that contains valuable proteins used to
treat burn victims, bleeding disorders, human immune deficiencies and other
chronic or genetic disorders. Unlike other blood components, which are stored
at room temperature or refrigerated, plasma is frozen and thawed prior to
fractionation or transfusion.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com) is a leading global health care
company that focuses on pharmaceuticals and medical devices used to care for
critically and chronically ill patients inside and outside the hospital.
Fresenius Kabi products include intravenous specialty and generic medicines,
infusion therapies, clinical nutrition and related medical devices. Within
transfusion technologies, Fresenius Kabi offers products for whole blood
collection and processing as well as for transfusion medicine and cell
therapies. The company’s roots go back more than 100 years to the founding of
its parent company, Fresenius SE, in Bad Homburg, Germany, where the company
is headquartered today.

Acquired by Fresenius Kabi in December 2012, Fenwal (www.fenwalinc.com) is
focused on improving transfusion medicine through expertise in blood
separation, collection, filtration, storage and transfusion. Fenwal offers a
broad range of products and services for the automated and manual collection
of blood and blood components.


Media contact
Fresenius Kabi
Matt Kuhn
Press spacebar to pause and continue. Press esc to stop.